Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab | Synapse
April 12, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
Puntos clave
To investigate how intrahepatic tumor burden affects outcomes in patients with hepatocellular carcinoma and extrahepatic metastases.
Analyzed patients with metastatic hepatocellular carcinoma
Received treatment with atezolizumab and bevacizumab
Evaluated overall survival related to intrahepatic tumor burden
Intrahepatic tumor burden correlated with overall survival rates
High tumor burden associated with poorer outcomes
Findings may inform risk stratification and treatment optimization
Resumen
In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.